Trump Administration Drives Down Medicare Advantage and Part D Premiums for Seniors
(Source – cms.gov/newsroom) Ahead of Medicare Open Enrollment, the Centers for Medicare & Medicaid Services (CMS), under the leadership of
Read More
Part D/Prescription Drugs
Americans pay up to 67 times more for drugs than other countries
(By Maia Anderson for Becker’s Hospital Review) A report released Sept. 23 by the House Ways & Means Committee shows that Americans
Read MoreMedicare Part D has led to an overall reduction in drug prices
Medicare Part D, which has been available to seniors since 2006, has affected drug prices. According to the Henry J.
Read MoreThe Democrats shepherding Pelosi’s drug pricing bill have taken plenty of campaign cash from pharma
(By Lev Facher for STAT) WASHINGTON — The fate of Nancy Pelosi’s sweeping drug pricing bill rests in the hands
Read MoreIn Tiny Doses, An Addiction Medication Moonlights As A Treatment For Chronic Pain
(By Alex Smith for NPR) Lori Pinkley, a 50-year-old from Kansas City, Mo., has struggled with puzzling chronic pain since
Read MoreAs Off-Label Use Spreads, Supplies Of Niche Drugs And Patients’ Patience Grow Short
(By Julie Appleby for Kaiser Health News) Medical treatment has knocked down tumors in 6-year-old Easton Daniels’ brain, but the
Read MoreHospitals earn greater profit from physician-administered meds than drugmakers, study finds
(By Alia Paavola for Becker’s Hospital Review) Hospitals earn a greater profit from physician-administered drugs than pharmaceutical manufacturers themselves, according
Read MoreHill Hodgepodge: Pelosi Draws From Democrats, GOP And Trump For Drug Plan
(By Emmarie Huetteman for Kaiser Health News) House Democratic leaders on Thursday unveiled an aggressive plan to lower drug prices
Read MoreWhy didn’t nonprofits and the NIH require ‘reasonable’ pricing for Zolgensma? That may happen in France
(By James Love for STAT) When a new drug emerges from research largely funded by grants from charities and government
Read MoreInspector general: Part D rebates grew, but not enough to offset drug price hikes
(By Maia Anderson for Becker’s Hospital Review) Although rebates for brand-name drugs in Medicare Part D substantially reduced drug spending,
Read More